Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However...
Gespeichert in:
| Veröffentlicht in: | Angewandte Chemie International Edition 2024-11, p.e202420510 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | e202420510 |
| container_title | Angewandte Chemie International Edition |
| container_volume | |
| creator | Panek, Dawid Pasieka, Anna Jończyk, Jakub Gawlińska, Milena Zaręba, Paula Siwek, Agata Wolak, Małgorzata Mordyl, Barbara Głuch-Lutwin, Monika Latacz, Gniewomir Brazzolotto, Xavier Chantegreil, Fabien Nachon, Florian Zdarova Karasova, Jana Pejchal, Jaroslav Mzik, Martin Sestak, Vit Prchal, Lukas Odvarkova, Jitka Soukup, Ondrej Korabecny, Jan Sorf, Ales Hamsikova, Marie Zemanova, Lucie Muckova, Lubica Vánova, Nela Dryja, Pola Sałat, Kinga Höfner, Georg Wanner, Klaus Więckowska, Anna Malawska, Barbara |
| description | Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However, imbalances in other neurotransmitters, such as γ-aminobutyric acid (GABA), also contribute to AD symptomatology. In the presented research, using a combination of crystallography and computational methods we developed compound 6 as a dual modulator of GABAergic and cholinergic neurotransmission systems. Compound 6 demonstrated inhibition of BuChE (IC
=0.21 μM) and GABA transporter 1 (IC
=10.96 μM) and 3 (IC
=7.76 μM), along with a favorable drug-likeness profile. Subsequent in vivo studies revealed the effectiveness of 6 in enhancing memory retention and alleviating anxiety and depression symptoms in animal models, while also proving safe and bioavailable for oral administration. The innovative multi-target-directed ligand 6 offers a new approach to treating cognitive deficits and BPSD in AD. |
| doi_str_mv | 10.1002/anie.202420510 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3128748741</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3128748741</sourcerecordid><originalsourceid>FETCH-LOGICAL-c220t-9d7271029a6b61db2e0ffbd9beebfea237ccadf498e61d01c0d5cc60900dec513</originalsourceid><addsrcrecordid>eNo9UctuVDEMjRCIlsKWJcoOFtxpHnNfy-mUlkp9sCjrK9_EaYNyk5JHJfo5fCkZTalkybZ8zrGtQ8hHzlacMXEM3uJKMLEWrOXsFTnkreCN7Hv5utZrKZt-aPkBeZfSr4ofBta9JQdybIUcuu6Q_L0qLltTvMo2eHBf6ZkrIaLH5gQSanoVdHGQQ6TB0O19cNZjvLOKgtf0fHOy2XfXWGLIEXxabEpVikKiQK_DIzp6Gssd3VaC1ZCRmir2A5yzkO0j0tuIkBf0ebdh457u0S4YPyd6ahPWG96TNwZcwg_P-Yj8PPt2u_3eXN6cX2w3l40SguVm1L3oORMjdHPH9SyQGTPrcUacDYKQvVKgzXocsI4ZV0y3SnVsZEyjark8Il_2ug8x_C6Y8lRfUegceAwlTZKLoV_X2EFXe6iKIaWIZnqIdoH4Z-Js2vky7XyZXnyphE_P2mVeUL_A_xsh_wE7vYzJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128748741</pqid></control><display><type>article</type><title>Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Panek, Dawid ; Pasieka, Anna ; Jończyk, Jakub ; Gawlińska, Milena ; Zaręba, Paula ; Siwek, Agata ; Wolak, Małgorzata ; Mordyl, Barbara ; Głuch-Lutwin, Monika ; Latacz, Gniewomir ; Brazzolotto, Xavier ; Chantegreil, Fabien ; Nachon, Florian ; Zdarova Karasova, Jana ; Pejchal, Jaroslav ; Mzik, Martin ; Sestak, Vit ; Prchal, Lukas ; Odvarkova, Jitka ; Soukup, Ondrej ; Korabecny, Jan ; Sorf, Ales ; Hamsikova, Marie ; Zemanova, Lucie ; Muckova, Lubica ; Vánova, Nela ; Dryja, Pola ; Sałat, Kinga ; Höfner, Georg ; Wanner, Klaus ; Więckowska, Anna ; Malawska, Barbara</creator><creatorcontrib>Panek, Dawid ; Pasieka, Anna ; Jończyk, Jakub ; Gawlińska, Milena ; Zaręba, Paula ; Siwek, Agata ; Wolak, Małgorzata ; Mordyl, Barbara ; Głuch-Lutwin, Monika ; Latacz, Gniewomir ; Brazzolotto, Xavier ; Chantegreil, Fabien ; Nachon, Florian ; Zdarova Karasova, Jana ; Pejchal, Jaroslav ; Mzik, Martin ; Sestak, Vit ; Prchal, Lukas ; Odvarkova, Jitka ; Soukup, Ondrej ; Korabecny, Jan ; Sorf, Ales ; Hamsikova, Marie ; Zemanova, Lucie ; Muckova, Lubica ; Vánova, Nela ; Dryja, Pola ; Sałat, Kinga ; Höfner, Georg ; Wanner, Klaus ; Więckowska, Anna ; Malawska, Barbara</creatorcontrib><description>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However, imbalances in other neurotransmitters, such as γ-aminobutyric acid (GABA), also contribute to AD symptomatology. In the presented research, using a combination of crystallography and computational methods we developed compound 6 as a dual modulator of GABAergic and cholinergic neurotransmission systems. Compound 6 demonstrated inhibition of BuChE (IC
=0.21 μM) and GABA transporter 1 (IC
=10.96 μM) and 3 (IC
=7.76 μM), along with a favorable drug-likeness profile. Subsequent in vivo studies revealed the effectiveness of 6 in enhancing memory retention and alleviating anxiety and depression symptoms in animal models, while also proving safe and bioavailable for oral administration. The innovative multi-target-directed ligand 6 offers a new approach to treating cognitive deficits and BPSD in AD.</description><identifier>ISSN: 1433-7851</identifier><identifier>ISSN: 1521-3773</identifier><identifier>EISSN: 1521-3773</identifier><identifier>DOI: 10.1002/anie.202420510</identifier><identifier>PMID: 39523866</identifier><language>eng</language><publisher>Germany</publisher><ispartof>Angewandte Chemie International Edition, 2024-11, p.e202420510</ispartof><rights>2024 The Author(s). Angewandte Chemie International Edition published by Wiley-VCH GmbH.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c220t-9d7271029a6b61db2e0ffbd9beebfea237ccadf498e61d01c0d5cc60900dec513</cites><orcidid>0000-0002-9731-908X ; 0000-0001-7906-0353 ; 0000-0001-9698-4478 ; 0000-0001-6977-7596 ; 0000-0002-2732-5935 ; 0000-0003-0614-5393 ; 0000-0002-5037-6183 ; 0000-0002-4688-2577 ; 0000-0001-6693-6061 ; 0000-0001-9247-2598 ; 0000-0001-5321-9266 ; 0000-0001-9219-1032 ; 0000-0001-5982-8265 ; 0000-0001-6376-8701 ; 0000-0002-3211-7188 ; 0009-0009-0628-9865 ; 0000-0003-2228-7922 ; 0000-0002-1827-9308 ; 0000-0003-4637-5820 ; 0000-0003-0293-2429 ; 0000-0003-1632-6569 ; 0000-0001-7829-3980 ; 0000-0003-4399-1425 ; 0000-0003-0891-9591 ; 0000-0002-5426-9123 ; 0000-0002-3161-0878 ; 0000-0003-4649-7828 ; 0000-0002-7957-4503</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39523866$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Panek, Dawid</creatorcontrib><creatorcontrib>Pasieka, Anna</creatorcontrib><creatorcontrib>Jończyk, Jakub</creatorcontrib><creatorcontrib>Gawlińska, Milena</creatorcontrib><creatorcontrib>Zaręba, Paula</creatorcontrib><creatorcontrib>Siwek, Agata</creatorcontrib><creatorcontrib>Wolak, Małgorzata</creatorcontrib><creatorcontrib>Mordyl, Barbara</creatorcontrib><creatorcontrib>Głuch-Lutwin, Monika</creatorcontrib><creatorcontrib>Latacz, Gniewomir</creatorcontrib><creatorcontrib>Brazzolotto, Xavier</creatorcontrib><creatorcontrib>Chantegreil, Fabien</creatorcontrib><creatorcontrib>Nachon, Florian</creatorcontrib><creatorcontrib>Zdarova Karasova, Jana</creatorcontrib><creatorcontrib>Pejchal, Jaroslav</creatorcontrib><creatorcontrib>Mzik, Martin</creatorcontrib><creatorcontrib>Sestak, Vit</creatorcontrib><creatorcontrib>Prchal, Lukas</creatorcontrib><creatorcontrib>Odvarkova, Jitka</creatorcontrib><creatorcontrib>Soukup, Ondrej</creatorcontrib><creatorcontrib>Korabecny, Jan</creatorcontrib><creatorcontrib>Sorf, Ales</creatorcontrib><creatorcontrib>Hamsikova, Marie</creatorcontrib><creatorcontrib>Zemanova, Lucie</creatorcontrib><creatorcontrib>Muckova, Lubica</creatorcontrib><creatorcontrib>Vánova, Nela</creatorcontrib><creatorcontrib>Dryja, Pola</creatorcontrib><creatorcontrib>Sałat, Kinga</creatorcontrib><creatorcontrib>Höfner, Georg</creatorcontrib><creatorcontrib>Wanner, Klaus</creatorcontrib><creatorcontrib>Więckowska, Anna</creatorcontrib><creatorcontrib>Malawska, Barbara</creatorcontrib><title>Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease</title><title>Angewandte Chemie International Edition</title><addtitle>Angew Chem Int Ed Engl</addtitle><description>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However, imbalances in other neurotransmitters, such as γ-aminobutyric acid (GABA), also contribute to AD symptomatology. In the presented research, using a combination of crystallography and computational methods we developed compound 6 as a dual modulator of GABAergic and cholinergic neurotransmission systems. Compound 6 demonstrated inhibition of BuChE (IC
=0.21 μM) and GABA transporter 1 (IC
=10.96 μM) and 3 (IC
=7.76 μM), along with a favorable drug-likeness profile. Subsequent in vivo studies revealed the effectiveness of 6 in enhancing memory retention and alleviating anxiety and depression symptoms in animal models, while also proving safe and bioavailable for oral administration. The innovative multi-target-directed ligand 6 offers a new approach to treating cognitive deficits and BPSD in AD.</description><issn>1433-7851</issn><issn>1521-3773</issn><issn>1521-3773</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9UctuVDEMjRCIlsKWJcoOFtxpHnNfy-mUlkp9sCjrK9_EaYNyk5JHJfo5fCkZTalkybZ8zrGtQ8hHzlacMXEM3uJKMLEWrOXsFTnkreCN7Hv5utZrKZt-aPkBeZfSr4ofBta9JQdybIUcuu6Q_L0qLltTvMo2eHBf6ZkrIaLH5gQSanoVdHGQQ6TB0O19cNZjvLOKgtf0fHOy2XfXWGLIEXxabEpVikKiQK_DIzp6Gssd3VaC1ZCRmir2A5yzkO0j0tuIkBf0ebdh457u0S4YPyd6ahPWG96TNwZcwg_P-Yj8PPt2u_3eXN6cX2w3l40SguVm1L3oORMjdHPH9SyQGTPrcUacDYKQvVKgzXocsI4ZV0y3SnVsZEyjark8Il_2ug8x_C6Y8lRfUegceAwlTZKLoV_X2EFXe6iKIaWIZnqIdoH4Z-Js2vky7XyZXnyphE_P2mVeUL_A_xsh_wE7vYzJ</recordid><startdate>20241122</startdate><enddate>20241122</enddate><creator>Panek, Dawid</creator><creator>Pasieka, Anna</creator><creator>Jończyk, Jakub</creator><creator>Gawlińska, Milena</creator><creator>Zaręba, Paula</creator><creator>Siwek, Agata</creator><creator>Wolak, Małgorzata</creator><creator>Mordyl, Barbara</creator><creator>Głuch-Lutwin, Monika</creator><creator>Latacz, Gniewomir</creator><creator>Brazzolotto, Xavier</creator><creator>Chantegreil, Fabien</creator><creator>Nachon, Florian</creator><creator>Zdarova Karasova, Jana</creator><creator>Pejchal, Jaroslav</creator><creator>Mzik, Martin</creator><creator>Sestak, Vit</creator><creator>Prchal, Lukas</creator><creator>Odvarkova, Jitka</creator><creator>Soukup, Ondrej</creator><creator>Korabecny, Jan</creator><creator>Sorf, Ales</creator><creator>Hamsikova, Marie</creator><creator>Zemanova, Lucie</creator><creator>Muckova, Lubica</creator><creator>Vánova, Nela</creator><creator>Dryja, Pola</creator><creator>Sałat, Kinga</creator><creator>Höfner, Georg</creator><creator>Wanner, Klaus</creator><creator>Więckowska, Anna</creator><creator>Malawska, Barbara</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9731-908X</orcidid><orcidid>https://orcid.org/0000-0001-7906-0353</orcidid><orcidid>https://orcid.org/0000-0001-9698-4478</orcidid><orcidid>https://orcid.org/0000-0001-6977-7596</orcidid><orcidid>https://orcid.org/0000-0002-2732-5935</orcidid><orcidid>https://orcid.org/0000-0003-0614-5393</orcidid><orcidid>https://orcid.org/0000-0002-5037-6183</orcidid><orcidid>https://orcid.org/0000-0002-4688-2577</orcidid><orcidid>https://orcid.org/0000-0001-6693-6061</orcidid><orcidid>https://orcid.org/0000-0001-9247-2598</orcidid><orcidid>https://orcid.org/0000-0001-5321-9266</orcidid><orcidid>https://orcid.org/0000-0001-9219-1032</orcidid><orcidid>https://orcid.org/0000-0001-5982-8265</orcidid><orcidid>https://orcid.org/0000-0001-6376-8701</orcidid><orcidid>https://orcid.org/0000-0002-3211-7188</orcidid><orcidid>https://orcid.org/0009-0009-0628-9865</orcidid><orcidid>https://orcid.org/0000-0003-2228-7922</orcidid><orcidid>https://orcid.org/0000-0002-1827-9308</orcidid><orcidid>https://orcid.org/0000-0003-4637-5820</orcidid><orcidid>https://orcid.org/0000-0003-0293-2429</orcidid><orcidid>https://orcid.org/0000-0003-1632-6569</orcidid><orcidid>https://orcid.org/0000-0001-7829-3980</orcidid><orcidid>https://orcid.org/0000-0003-4399-1425</orcidid><orcidid>https://orcid.org/0000-0003-0891-9591</orcidid><orcidid>https://orcid.org/0000-0002-5426-9123</orcidid><orcidid>https://orcid.org/0000-0002-3161-0878</orcidid><orcidid>https://orcid.org/0000-0003-4649-7828</orcidid><orcidid>https://orcid.org/0000-0002-7957-4503</orcidid></search><sort><creationdate>20241122</creationdate><title>Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease</title><author>Panek, Dawid ; Pasieka, Anna ; Jończyk, Jakub ; Gawlińska, Milena ; Zaręba, Paula ; Siwek, Agata ; Wolak, Małgorzata ; Mordyl, Barbara ; Głuch-Lutwin, Monika ; Latacz, Gniewomir ; Brazzolotto, Xavier ; Chantegreil, Fabien ; Nachon, Florian ; Zdarova Karasova, Jana ; Pejchal, Jaroslav ; Mzik, Martin ; Sestak, Vit ; Prchal, Lukas ; Odvarkova, Jitka ; Soukup, Ondrej ; Korabecny, Jan ; Sorf, Ales ; Hamsikova, Marie ; Zemanova, Lucie ; Muckova, Lubica ; Vánova, Nela ; Dryja, Pola ; Sałat, Kinga ; Höfner, Georg ; Wanner, Klaus ; Więckowska, Anna ; Malawska, Barbara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c220t-9d7271029a6b61db2e0ffbd9beebfea237ccadf498e61d01c0d5cc60900dec513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Panek, Dawid</creatorcontrib><creatorcontrib>Pasieka, Anna</creatorcontrib><creatorcontrib>Jończyk, Jakub</creatorcontrib><creatorcontrib>Gawlińska, Milena</creatorcontrib><creatorcontrib>Zaręba, Paula</creatorcontrib><creatorcontrib>Siwek, Agata</creatorcontrib><creatorcontrib>Wolak, Małgorzata</creatorcontrib><creatorcontrib>Mordyl, Barbara</creatorcontrib><creatorcontrib>Głuch-Lutwin, Monika</creatorcontrib><creatorcontrib>Latacz, Gniewomir</creatorcontrib><creatorcontrib>Brazzolotto, Xavier</creatorcontrib><creatorcontrib>Chantegreil, Fabien</creatorcontrib><creatorcontrib>Nachon, Florian</creatorcontrib><creatorcontrib>Zdarova Karasova, Jana</creatorcontrib><creatorcontrib>Pejchal, Jaroslav</creatorcontrib><creatorcontrib>Mzik, Martin</creatorcontrib><creatorcontrib>Sestak, Vit</creatorcontrib><creatorcontrib>Prchal, Lukas</creatorcontrib><creatorcontrib>Odvarkova, Jitka</creatorcontrib><creatorcontrib>Soukup, Ondrej</creatorcontrib><creatorcontrib>Korabecny, Jan</creatorcontrib><creatorcontrib>Sorf, Ales</creatorcontrib><creatorcontrib>Hamsikova, Marie</creatorcontrib><creatorcontrib>Zemanova, Lucie</creatorcontrib><creatorcontrib>Muckova, Lubica</creatorcontrib><creatorcontrib>Vánova, Nela</creatorcontrib><creatorcontrib>Dryja, Pola</creatorcontrib><creatorcontrib>Sałat, Kinga</creatorcontrib><creatorcontrib>Höfner, Georg</creatorcontrib><creatorcontrib>Wanner, Klaus</creatorcontrib><creatorcontrib>Więckowska, Anna</creatorcontrib><creatorcontrib>Malawska, Barbara</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Angewandte Chemie International Edition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Panek, Dawid</au><au>Pasieka, Anna</au><au>Jończyk, Jakub</au><au>Gawlińska, Milena</au><au>Zaręba, Paula</au><au>Siwek, Agata</au><au>Wolak, Małgorzata</au><au>Mordyl, Barbara</au><au>Głuch-Lutwin, Monika</au><au>Latacz, Gniewomir</au><au>Brazzolotto, Xavier</au><au>Chantegreil, Fabien</au><au>Nachon, Florian</au><au>Zdarova Karasova, Jana</au><au>Pejchal, Jaroslav</au><au>Mzik, Martin</au><au>Sestak, Vit</au><au>Prchal, Lukas</au><au>Odvarkova, Jitka</au><au>Soukup, Ondrej</au><au>Korabecny, Jan</au><au>Sorf, Ales</au><au>Hamsikova, Marie</au><au>Zemanova, Lucie</au><au>Muckova, Lubica</au><au>Vánova, Nela</au><au>Dryja, Pola</au><au>Sałat, Kinga</au><au>Höfner, Georg</au><au>Wanner, Klaus</au><au>Więckowska, Anna</au><au>Malawska, Barbara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease</atitle><jtitle>Angewandte Chemie International Edition</jtitle><addtitle>Angew Chem Int Ed Engl</addtitle><date>2024-11-22</date><risdate>2024</risdate><spage>e202420510</spage><pages>e202420510-</pages><issn>1433-7851</issn><issn>1521-3773</issn><eissn>1521-3773</eissn><abstract>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However, imbalances in other neurotransmitters, such as γ-aminobutyric acid (GABA), also contribute to AD symptomatology. In the presented research, using a combination of crystallography and computational methods we developed compound 6 as a dual modulator of GABAergic and cholinergic neurotransmission systems. Compound 6 demonstrated inhibition of BuChE (IC
=0.21 μM) and GABA transporter 1 (IC
=10.96 μM) and 3 (IC
=7.76 μM), along with a favorable drug-likeness profile. Subsequent in vivo studies revealed the effectiveness of 6 in enhancing memory retention and alleviating anxiety and depression symptoms in animal models, while also proving safe and bioavailable for oral administration. The innovative multi-target-directed ligand 6 offers a new approach to treating cognitive deficits and BPSD in AD.</abstract><cop>Germany</cop><pmid>39523866</pmid><doi>10.1002/anie.202420510</doi><orcidid>https://orcid.org/0000-0002-9731-908X</orcidid><orcidid>https://orcid.org/0000-0001-7906-0353</orcidid><orcidid>https://orcid.org/0000-0001-9698-4478</orcidid><orcidid>https://orcid.org/0000-0001-6977-7596</orcidid><orcidid>https://orcid.org/0000-0002-2732-5935</orcidid><orcidid>https://orcid.org/0000-0003-0614-5393</orcidid><orcidid>https://orcid.org/0000-0002-5037-6183</orcidid><orcidid>https://orcid.org/0000-0002-4688-2577</orcidid><orcidid>https://orcid.org/0000-0001-6693-6061</orcidid><orcidid>https://orcid.org/0000-0001-9247-2598</orcidid><orcidid>https://orcid.org/0000-0001-5321-9266</orcidid><orcidid>https://orcid.org/0000-0001-9219-1032</orcidid><orcidid>https://orcid.org/0000-0001-5982-8265</orcidid><orcidid>https://orcid.org/0000-0001-6376-8701</orcidid><orcidid>https://orcid.org/0000-0002-3211-7188</orcidid><orcidid>https://orcid.org/0009-0009-0628-9865</orcidid><orcidid>https://orcid.org/0000-0003-2228-7922</orcidid><orcidid>https://orcid.org/0000-0002-1827-9308</orcidid><orcidid>https://orcid.org/0000-0003-4637-5820</orcidid><orcidid>https://orcid.org/0000-0003-0293-2429</orcidid><orcidid>https://orcid.org/0000-0003-1632-6569</orcidid><orcidid>https://orcid.org/0000-0001-7829-3980</orcidid><orcidid>https://orcid.org/0000-0003-4399-1425</orcidid><orcidid>https://orcid.org/0000-0003-0891-9591</orcidid><orcidid>https://orcid.org/0000-0002-5426-9123</orcidid><orcidid>https://orcid.org/0000-0002-3161-0878</orcidid><orcidid>https://orcid.org/0000-0003-4649-7828</orcidid><orcidid>https://orcid.org/0000-0002-7957-4503</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1433-7851 |
| ispartof | Angewandte Chemie International Edition, 2024-11, p.e202420510 |
| issn | 1433-7851 1521-3773 1521-3773 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3128748741 |
| source | Wiley Online Library Journals Frontfile Complete |
| title | Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T04%3A56%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multifunctional,%20Fluorene-Based%20Modulator%20of%20Cholinergic%20and%20GABAergic%20Neurotransmission%20as%20a%20Novel%20Drug%20Candidate%20for%20Palliative%20Treatment%20of%20Alzheimer's%20Disease&rft.jtitle=Angewandte%20Chemie%20International%20Edition&rft.au=Panek,%20Dawid&rft.date=2024-11-22&rft.spage=e202420510&rft.pages=e202420510-&rft.issn=1433-7851&rft.eissn=1521-3773&rft_id=info:doi/10.1002/anie.202420510&rft_dat=%3Cproquest_cross%3E3128748741%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128748741&rft_id=info:pmid/39523866&rfr_iscdi=true |